009535334
WPI Acc No: 1993-228874/199329
Treatment of rheumatoid arthritis - using azauridine cpds., e.g. azaribine or 6-azauridine
Patent Assignee: UR LABS INC (URUR-N); UR LAB INC (URUR-N)
Inventor: DRELL W
Number of Countries: 021 Number of Patents: 006
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
EP 552057	A1	19930721	EP 93300267	A	19930115	199329	B
AU 9331832	A	19930722	AU 9331832	A	19930115	199336	
CA 2087147	A	19930718	CA 2087147	A	19930112	199341	
JP 5345723	A	19931227	JP 935610	A	19930118	199405	
US 5389617	A	19950214	US 92822630	A	19920117	199512	
			US 93152255	A	19931112		
AU 661364	B	19950720	AU 9331832	A	19930115	199537	

Priority Applications (No Type Date): US 92822630 A 19920117
Cited Patents: 6.Jnl.Ref; CA 1211375; US 5023083
Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
EP 552057	A1	E	7	A61K-031/70	
Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE					
JP 5345723	A		3	A61K-031/505	
US 5389617	A		3	A61K-031/70	Cont of application US 92822630
AU 661364	B			A61K-031/70	Previous Publ. patent AU 9331832
AU 9331832	A			A61K-031/70	
CA 2087147	A			A61K-031/53	

Abstract (Basic): EP 552057 A

The use of an azauridine cpd. for the treatment of rheumatoid arthritis is new. The cpd. is administered at 10-50 mg/kg/day for an initial period to reduce the adverse effects and then at above 50 mg/kg/day to relieve the rheumatoid arthritis.

Pref. the azauridine (pref. azaribine or 6-azauridine) is initially administered at 15-35 mg/kg/day for 1-4 weeks, at 50-100 mg/kg/day in the second period for 4-8 weeks and then at above 100 mg/kg/day for as long as the patient shows improvement. A pyrixoxine cpd. may also be administered (pref. at least 0.0005 moles/mole of azauridine).

USE/ADVANTAGE - Azaribine is an effective oral treatment for psoriasis, psoriatic arthritis, mycosis fungoides, herpes simplex and small pox. At higher doses azaribine has anti-inflammatory activity bu shows severe side effects (e.g. fever, joint pain, joint swelling, edema, nausea, emesis, exanthema, painful and rigid muscles and depression). The novel regime avoids these side effects. The erythrocyte sedimentation rate is reduced, the joint tenderness/pain index is improved, the join/swelling index is improved and the patients have a feeling of well being. The azaribine is pref. administered orally in a formulation which avoids absorption through the stomach and which contains a pyridoxal phosphate cpd. (pref. pyridoxine hydrochloride) pref. at above 0.025 mole/mole azaribine (to avoid pyridoxal phosphate deficiency). Administriation of 6-azauridine has to be done i.v. to avoid metabolism by intestinal bacteria to 6-azauracil which is toxic

Dwg.0/0

Abstract (Equivalent): US 5389617 A

Treating rheumatoid arthritis comprises: (a) admin. of 10-50 mg/kg/day azauridine (AZ) cpd. and at least 0.0005 moles pyridoxine (PY) per mole AZ, for a period to reduce the adverse side effects associated with admin. of AZ cpds. at dosage levels of at least 50 mg/kg/day; and then (b) admin. of a higher dose level of at least 50 mg/kg/day AZ cpd. and at least 0.005 moles PY per mole AZ, to show improvement in rheumatoid arthritis.

Pref. the first period is 1-4 weeks using 15-35 mg/kg/day AZ cpd. and the second is 4-8 weeks, using at least 100 mg/kg/day AZ cpd.

The AZ cpd. is azaribine or 6-azauridine. Admin. is esp. by i.v. infusion or is oral, AZ being encapsulated in an enteric coating.

USE/ADVANTAGE - Admin. of AZ cpd. reduces erythrocyte sedimentation rate, improves joint tenderness/pain index, joint swelling index and feeling of well being. The method does not have the adverse side effects associated with prior art.

Dwg.0/0

Derwent Class: B03
International Patent Class (Main): A61K-031/505; A61K-031/53; A61K-031/70
International Patent Class (Additional): A61K-009/08; A61K-009/28; A61K-031/44

009342661
WPI Acc No: 1993-036125/199304

Oral compsn. contg. therapeutic protein, esp. allergen or antigen - stabilised by inactive protein and coated with enteric polymer, used as vaccines and to treat allergies

Patent Assignee: UNIV CINCINNATI (UYCI-N)
Inventor: MICHAEL J G; LITWIN A
Number of Countries: 037 Number of Patents: 010
Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
WO 9300077	A1	19930107	WO 92US5004	A	19920611	199304	B
AU 9222496	A	19930125	AU 9222496	A	19920611	199319	
EP 590060	A1	19940406	EP 92914240	A	19920611	199414	
			WO 92US5004	A	19920611		
JP 6508371	W	19940922	WO 92US5004	A	19920611	199442	
			JP 93501524	A	19920611		
EP 590060	A4	19940525	EP 92914240	A		199531	
AU 664561	B	19951123	AU 9222496	A	19920611	199603	
EP 590060	B1	19970917	EP 92914240	A	19920611	199742	
			WO 92US5004	A	19920611		
DE 69222306	E	19971023	DE 622306	A	19920611	199748	
			EP 92914240	A	19920611		
			WO 92US5004	A	19920611		
ES 2109362	T3	19980116	EP 92914240	A	19920611	199810	
US 6174529	B1	20010116	US 91719160	A	19910621	200106	
			US 92994932	A	19921222		
			US 94178503	A	19940107		
			US 94329685	A	19941026		
			US 95472711	A	19950605		
			US 97947551	A	19971011		

Priority Applications (No Type Date): US 91719160 A 19910621; US 92994932 A 19921222; US 94178503 A 19940107; US 94329685 A 19941026; US 95472711 A 19950605; US 97947551 A 19971011